Abrogation of Anti-HLA Antibodies via Proteasome Inhibition

2009164 citationsJournal Article

Authors

Hargovind L. Trivedi · Institute of Transplantation Sciences

Paul I. Terasaki · Terasaki Foundation

A Feroz

Matthew J. Everly · Terasaki Foundation

Aruna V. Vanikar · Institute of Transplantation Sciences

Vangipurapu Shankar · Shree Krishna Hospital

Varsha B. Trivedi · Institute of Transplantation Sciences

Abstract

Bortezomib therapy effectively abrogates anti-HLA antibodies. Hence, removal of antibodies, by proteasome inhibition, represents a new treatment strategy for transplantation and may have benefit in autoimmune-related disease.

Topics & Keywords

Multiple Myeloma Research and Treatments T-cell and B-cell Immunology Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Transplantation

Volume 87, Issue 10, pp. 1555-1561

DOI: 10.1097/tp.0b013e3181a4b91b

Field-Weighted Citation Impact: 14.23